# Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS

Source: https://onco.cc/trials/nct03699475/  
OnCo record `nct03699475` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Rivogenlecleucel run by Bellicum Pharmaceuticals, terminated.

## Summary

Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS is a phase 2/3 interventional study registered as NCT03699475 by Bellicum Pharmaceuticals, with 1 participants enrolled, started 2018-12-27. Conditions recorded: Acute Myeloid Leukemia and Myelodysplastic Syndromes. Interventions recorded: rivogenlecleucel, rimiducid, Cyclophosphamide and haplo-HSCT.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03699475
- Phase: 2/3
- Setting: A Randomized Phase II/III Study of αβ T Cell-Depleted, Related, Haploidentical Hematopoietic Stem Cell Transplant (Haplo-HSCT) Plus Rivogenlecleucel vs. Haplo-HSCT Plus Post-Transplant Cyclophosphamide (PTCy) in Patients With AML or MDS
- Sponsor: Bellicum Pharmaceuticals
- Enrolled: 1

## Sources

- ClinicalTrials.gov NCT03699475: https://clinicaltrials.gov/study/NCT03699475

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- drugs: [Rivogenlecleucel](https://onco.cc/drugs/rivogenlecleucel/)
- companies: [Bellicum Pharmaceuticals](https://onco.cc/companies/bellicum/)

---
JSON: https://onco.cc/api/v1/entities/nct03699475.json